{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-26-009289","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.276424+00:00","generated_at":"2026-05-15T01:40:56.180192+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tonix presents TNX-4800 Phase 1 data; plans adaptive Phase 2 field study for Lyme disease prevention in H1 2027","bullets":["Phase 1 data of TNX-4800 (anti-OspA mAb) for Lyme disease presented at Ticks and Tickborne Diseases Symposium.","Planned adaptive Phase 2 field study: two-dose SC regimen, primary endpoint 6-month protection; start H1 2027 pending FDA agreement.","FDA Type C meeting scheduled early Q3 2026 to discuss Phase 2 study design.","Each fixed subcutaneous dose expected to provide exposure comparable to 5 mg/kg dose in Phase 1."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-26-009289","json":"https://secwatch.observer/filing/0001999371-26-009289.json","markdown":"https://secwatch.observer/filing/0001999371-26-009289.md","text":"https://secwatch.observer/filing/0001999371-26-009289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126009289/0001999371-26-009289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126009289/tnxp_8k-0422926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:40:56.180192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}